GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest a bullish outlook, but reimbursement and competition remain key risks.
Market read
Strong earnings and guidance lift for GKOS may influence related eye‑care stocks and sector sentiment.
What to watch
Potential delays in Medicare coverage decisions for iDose TR and payer adoption for Epioxa.
Background
Glaukos (GKOS) reported a record Q2 with 49.5% revenue growth and raised full‑year guidance, driven by iDose TR and new corneal product Epioxa.
Ticker impact
Q2 results show 49.5% revenue jump to $185.6M and management raises 2026 revenue guidance by $60‑$65M.
upside pressure over the next few weeks
Revenue growth and guidance lift exceed expectations, narrowing loss estimates and expanding market addressable.
Market effects
Positive momentum for ophthalmology and eye‑care device sector.
U.S. eye‑care market sees increased adoption; international expansion adds upside.
Highlights growth potential for interventional glaucoma therapies worldwide.
Counterpoint
Reimbursement risk and competitive pressure could temper upside.
Key entities
- companyGlaukos Corporation
US‑listed ophthalmology device maker (ticker GKOS).
